Shoulder Innovations, Inc.
NYSE:SIMedical - Specialties
-$0.13 today
- Market cap
- $432.04M
- Beta
- -1.07
- P/E (TTM)
- -8.4
- EPS (TTM)
- -$2.13
Volume 0.09M
Average 0.10M
SI Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Shoulder Innovations, Inc.NYSE: SI
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $3.75M rose 137.1% year over year, ahead of the +98.0% change in trailing-twelve-month research & development. Sequentially, it rose 16.7% from the prior quarter.
Context
- Research & development amounted to 16.3% of revenue in FY2025, up 2.1 pp from a year earlier.
- Research & development increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly growth of +137.1% holds above the trailing-twelve-month pace of +98.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 7.73M USD
- Year-over-year change
- +72.2%
- 2-year CAGR
- +60.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.73M | +72.2% |
| FY2024 | 2024-12-31 | 4.49M | +48.6% |
| FY2023 | 2023-12-31 | 3.02M | — |
Research & Development vs competitors
How SI compares with its peers on the latest reported figures
- SI's LTM Mar 2026 research & development of $9.9M is the 10th highest of the 11 companies compared; the peer median is $24.26M.
- Its year-over-year change of +98.0% is the 3rd highest of 11, against a peer median of +2.7%.
- Research & development amounts to 18.4% of revenue for SI, versus a peer median of 18.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $91.32M | -20.8% | -13.4% | 131.9% | |
| LTM Mar 2026 | $64.86M | +10.1% | -2.5% | 91.2% | |
| LTM Mar 2026 | $57.75M | +141.5% | +89.7% | — | |
| LTM Mar 2026 | $40.3M | -12.6% | +4.1% | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $27.18M | +72.6% | +29.4% | — |
| LTM Mar 2026 | $21.34M | -31.8% | -24.3% | 18.1% | |
| LTM Mar 2026 | $20.46M | +7.3% | -4.0% | 5.8% | |
| LTM Dec 2025 | $19.24M | -4.7% | -10.1% | 147.7% | |
| FY2025 | $10.35M | -1.9% | +11.1% | 9.6% | |
| LTM Mar 2026 | $9.9M | +98.0% | — | 18.4% | |
| LTM Mar 2026 | $1.81M | +151.4% | +33.6% | 4.1% | |
| Peer median (excluding SI) | $24.26M | +2.7% | +0.8% | 18.1% | |
Competitors are the stored peer set for SI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 19.27M | 31.62M | 47.32M |
| Cost of Revenue | 4M | 7.28M | 11.12M |
| Gross Profit | 15.27M | 24.34M | 36.2M |
| Gross Margin | 79.2% | 77.0% | 76.5% |
| Research & Development | 3.02M | 4.49M | 7.73M |
| Selling, General & Admin | 23.11M | 34.51M | 54.77M |
| Operating Expenses | 26.13M | 38.99M | 62.5M |
| Depreciation & Amortization | 1.64M | 2.2M | 3.21M |
| EBITDA | (10.25M) | (12.11M) | (37.08M) |
| EBITDA Margin | -53.2% | -38.3% | -78.4% |
| Operating Income | (10.86M) | (14.65M) | (26.3M) |
| Operating Margin | -56.4% | -46.3% | -55.6% |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 761K | 1.32M | 70K |
| Other Income / Expenses | (1.79M) | (966K) | (14.06M) |
| Income Before Tax | (12.66M) | (15.62M) | (40.36M) |
| Pre-Tax Margin | -65.7% | -49.4% | -85.3% |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (12.66M) | (15.62M) | (40.36M) |
| Net Margin | -65.7% | -49.4% | -85.3% |
| EPS (Basic) | (0.63) | (0.77) | (1.96) |
| EPS (Diluted) | (0.63) | (0.77) | (1.96) |
| Weighted Avg Shares | 19.92M | 19.92M | 20.63M |
| Weighted Avg Shares (Diluted) | 19.92M | 19.92M | 20.63M |
Shoulder Innovations, Inc.
NYSE:SI
Intrinsic Alpha fair value
Locked
Current Price
$20.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.